The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Open accessAbstract
BACKGROUND: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of nintedanib in patients with ILD associated with systemic sclerosis. Patients who had systemic sclerosis with an onset of the first non-Raynaud's symptom within the past 7 years and a high-resolution computed tomographic scan that showed fibrosis affecting at least 10% of the lungs were randomly assigned, in a 1:1 ratio, to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over a 52-week period. Key secondary end points were absolute changes from baseline in the modified Rodnan skin score and in the total score on the St. George's Respiratory Questionnaire (SGRQ) at week 52. RESULTS: A total of 576 patients received at least one dose of nintedanib or placebo; 51.9% had diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenolate at baseline. In the primary end-point analysis, the adjusted annual rate of change in FVC was -52.4 ml per year in the nintedanib group and -93.3 ml per year in the placebo group (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P = 0.04). Sensitivity analyses based on multiple imputation for missing data yielded P values for the primary end point ranging from 0.06 to 0.10. The change from baseline in the modified Rodnan skin score and the total score on the SGRQ at week 52 did not differ significantly between the trial groups, with differences of -0.21 (95% CI, -0.94 to 0.53; P = 0.58) and 1.69 (95% CI, -0.73 to 4.12 [not adjusted for multiple comparisons]), respectively. Diarrhea, the most common adverse event, was reported in 75.7% of the patients in the nintedanib group and in 31.6% of those in the placebo group. CONCLUSIONS: Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintedanib than with placebo. (Funded by Boehringer Ingelheim; SENSCIS ClinicalTrials.gov number, NCT02597933.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This observation is therefore in accordance with recent clinical trials showing that antifibrotic therapies are effective in progressive fibrotic interstitial lung diseases other than IPF [20,26,27].”
In the citing paper
“nintedanib has also now been approved for systemic sclerosis (SSc)-associated ILD (SSc-ILD), based on the positive outcome of Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial (Distler et al., 2019).”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Distler et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationvan den Hoogen, F. H. J., Khanna, D., Fransen, J., Johnson, S. R., Baron, M. G., Tyndall, A., Matucci‐Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204424 · Cited by 2,881
Self-citationThe St George's Respiratory Questionnaire
Jones, P., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,729
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationInterstitial Lung Disease in Systemic Sclerosis
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J. C., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,249
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J. G., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,077
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationWalker, U. A., Tyndall, A., Czirják, L., Denton, C. P., Farge, D., Kowal‐Bielecka, O., Müller‐Ladner, U., Bocelli‐Tyndall, C., & Matucci‐Cerinic, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062901 · Cited by 927
Cited by
Sorted by citations
Items 101–200 of 1,000
Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment
Hervier, B., & Uzunhan, Y. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2019.00326 · Cited by 77
Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need
Herrick, A. L., Assassi, S., & Denton, C. P. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00765-9 · Cited by 75
Cottin, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0109-2019 · Cited by 75
Khanna, D., Huang, S., Lin, C. J. F., & Spino, C. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219100 · Cited by 74
Refractory Sarcoidosis: A Review
Jammal, T. E., Jamilloux, Y., Gerfaud‐Valentin, M., Valeyre, D., & Sève, P. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s192922 · Cited by 74
Papazoglou, A., Huang, M., Bulik, M., Lafyatis, A., Tabib, T., Morse, C., Sembrat, J., Rojas, M. M., Valenzi, E., & Lafyatis, R. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42286 · Cited by 74
Antoniou, K. M., Distler, O., Gheorghiu, A.-M., Moor, C. C., Vikse, J., Bizymi, N., Galetti, I., Brown, G., Bargagli, E., Allanore, Y., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.02533-2024 · Cited by 81
Self-citationInterstitial Pneumonia With Autoimmune Features (IPAF)
Fernandes, L., Nasser, M., Ahmad, K., & Cottin, V. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00209 · Cited by 72
Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis
Adegunsoye, A., Morisset, J., Newton, C. A., Oldham, J. M., Vittinghoff, E., Linderholm, A., Strek, M. E., Noth, I., Garcia, C. K., Wolters, P. J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02872-2020 · Cited by 72
Immunomodulatory treatment of interstitial lung disease
van den Bosch, L., Luppi, F., Ferrara, G., & Mura, M. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666221117002 · Cited by 74
Elhaï, M., Avouac, J., & Allanore, Y. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.01.006 · Cited by 73
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Cottin, V., Richeldi, L., Rosas, I. O., Otaola, M., Song, J. W., Tomassetti, S., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01668-1 · Cited by 71
Self-citationMyositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management
Hallowell, R. W., & Paik, J. J. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/brvl1v · Cited by 72
JAK inhibitors and systemic sclerosis: A systematic review of the literature
Moriana, C., Moulinet, T., Jaussaud, R., & Decker, P. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103168 · Cited by 71
Nikkho, S. M., Richter, M. J., Shen, E., Abman, S. H., Antoniou, K., Chung, J. H., Fernandes, P., Hassoun, P. M., Lazarus, H. M., Olschewski, H., et al. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12127 · Cited by 70
Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Ghazipura, M., Mammen, M. J., Herman, D. D., Hon, S. M., Bissell, B. D., Macrea, M. M., Kheir, F. M., Khor, Y. H., Knight, S. L., Raghu, G., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202103-343oc · Cited by 69
Self-citationKuwana, M., Gil‐Vila, A., & Selva-O’Callaghan, A. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211032457 · Cited by 69
Self-citationCampochiaro, C., & Allanore, Y. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02536-5 · Cited by 66
Lescoat, A., Lecureur, V., & Varga, J. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000835 · Cited by 69
Long COVID-19 Pulmonary Sequelae and Management Considerations
Boutou, A., Asimakos, A., Kortianou, E. A., Vogiatzis, I., & Τzouvelekis, Α. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090838 · Cited by 67
Epiregulin is a dendritic cell–derived EGFR ligand that maintains skin and lung fibrosis
Odell, I. D., Steach, H. R., Gauld, S. B., Reinke-Breen, L., Kármán, J., Carr, T. L., Wetter, J. B., Phillips, L. A., Hinchcliff, M., & Flavell, R. A. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq6691 · Cited by 72
The role of vasculature and angiogenesis in respiratory diseases
Ackermann, M., Werlein, C., Plucinski, E. K., Leypold, S., Kühnel, M., Verleden, S. E., Khalil, H. A., Länger, F. P., Welte, T., Mentzer, S. J., et al. (2024) · Angiogenesis · doi:10.1007/s10456-024-09910-2 · Cited by 71
Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review
Laria, A., Lurati, A. M., Zizzo, G., Zaccara, E., Mazzocchi, D., Re, K. A., Marrazza, M., Faggioli, P. M., & Mazzone, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.837133 · Cited by 66
Vacchi, C., Sebastiani, M., Cassone, G., Cerri, S., Casa, G. D., Salvarani, C., & Manfredi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020407 · Cited by 68
Wang, Y., Chen, S., Zheng, S., Lin, J., Hu, S., Zhuang, J., Lin, Q., Xie, X., Zheng, K., Zhang, W., et al. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02586-9 · Cited by 63
Orvain, C., Boulch, M., Bousso, P., Allanore, Y., & Avouac, J. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41812 · Cited by 62
Cottin, V., Martínez, F. J., Smith, V. M., & Walsh, S. L. F. (2022) · European Respiratory Review · doi:10.1183/16000617.0003-2022 · Cited by 63
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions
Liakouli, V., Ciancio, A., Galdo, F. D., Giacomelli, R., & Ciccia, F. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01044-x · Cited by 62
Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis
Wijsenbeek, M. S., Swigris, J. J., Inoue, Y., Kreuter, M., Maher, T. M., Suda, T., Baldwin, M., Mueller, H., Rohr, K. B., & Flaherty, K. R. (2023) · European Respiratory Journal · doi:10.1183/13993003.00752-2023 · Cited by 65
Self-citationNintedanib: New indication for systemic sclerosis-associated interstitial lung disease
Kuwana, M., & Azuma, A. (2019) · Modern Rheumatology · doi:10.1080/14397595.2019.1696505 · Cited by 61
Self-citationAmati, F., Stainer, A., Polelli, V., Mantero, M., Gramegna, A., Blasi, F., & Aliberti, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097849 · Cited by 61
Olson, A. L., Patnaik, P., Hartmann, N., Bohn, R. L., Garry, E. M., & Wallace, L. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01786-8 · Cited by 62
Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?
Colletti, M., Galardi, A., Santis, M. D., Guidelli, G. M., Giannatale, A. D., Luigi, L. D., & Antinozzi, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184337 · Cited by 60
Volkmann, E. R. (2019) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198319889549 · Cited by 60
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis
Sgalla, G., Franciosa, C., Simonetti, J., & Richeldi, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1773790 · Cited by 59
Renaud, L., da Silveira, W. A., Takamura, N., Hardiman, G., & Feghali‐Bostwick, C. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00383 · Cited by 59
A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease
Patel, P., Marinock, J. M., Ajmeri, A., & Brent, L. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084453 · Cited by 65
Worrell, J. C., & O’Reilly, S. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102526 · Cited by 63
Stock, C. J. W., Hoyles, R. K., Daccord, C., Kokosi, M. A., Visca, D., Lauretis, A. D., Alfieri, V., Kouranos, V., Margaritopoulos, G. A., George, P. M., et al. (2020) · Respirology · doi:10.1111/resp.13988 · Cited by 58
Self-citationPulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57
Hoffmann‐Vold, A., Weigt, S. S., Saggar, R., Palchevskiy, V., Volkmann, E. R., Liang, L. L., Ross, D. J., Ardehali, A. A., Lynch, J. P., & Belperio, J. A. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.050 · Cited by 57
Management of systemic sclerosis: the first five years
Roofeh, D., & Khanna, D. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000711 · Cited by 59
Detection and Early Referral of Patients With Interstitial Lung Abnormalities
Hunninghake, G. M., Goldin, J. G., Kadoch, M. A., Kropski, J. A., Rosas, I. O., Wells, A. U., Yadav, R., Lazarus, H. M., Abtin, F. G., Corte, T. J., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.035 · Cited by 58
Self-citationMerkt, W., Zhou, Y., Han, H., & Lagares, D. (2021) · Wound Repair and Regeneration · doi:10.1111/wrr.12952 · Cited by 62
Hermansky–Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease
Yokoyama, T., & Gochuico, B. R. (2021) · European Respiratory Review · doi:10.1183/16000617.0193-2020 · Cited by 56
S1-Leitlinie Interdisziplinäre Diagnostik interstitieller Lungenerkrankungen im Erwachsenenalter
Kreuter, M., Behr, J., Bonella, F., Costabel, U., Gerber, A., Hamer, O. W., Heußel, C. P., Jonigk, D. D., Krause, A., Koschel, D., et al. (2023) · Pneumologie · doi:10.1055/a-2017-8971 · Cited by 55
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
Fischer, A., & Distler, J. H. W. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04720-0 · Cited by 55
Self-citationVolkmann, E. R., Tashkin, D. P., LeClair, H., Roth, M. D., Kim, G. H. J., Goldin, J. G., Clements, P. J., Furst, D. E., & Khanna, D. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11125 · Cited by 55
The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease
Hoffmann‐Vold, A., Allanore, Y., Bendstrup, E. M., Bruni, C., Distler, O., Maher, T. M., Wijsenbeek, M. S., & Kreuter, M. (2020) · Respiratory Research · doi:10.1186/s12931-020-01459-0 · Cited by 55
Self-citationThe Molecular Mechanisms of Systemic Sclerosis-Associated Lung Fibrosis
Mouawad, J. E., & Feghali‐Bostwick, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032963 · Cited by 56
Mackintosh, J. A., Keir, G. J., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., WILSHER, M. L., et al. (2024) · Respirology · doi:10.1111/resp.14656 · Cited by 54
Connective tissue disease-associated interstitial lung disease
Oliveira, R. P., Ribeiro, R., Melo, L., Grima, B., Oliveira, S., & Alves, J. D. (2020) · Pulmonology · doi:10.1016/j.pulmoe.2020.01.004 · Cited by 57
Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease
Avouac, J., Cauvet, A., Steelandt, A., Shirai, Y., Elhaï, M., Kuwana, M., Distler, O., & Allanore, Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232978 · Cited by 55
Self-citationLung Involvement in Primary Sjögren's Syndrome—An Under-Diagnosed Entity
Sogkas, G., Hirsch, S., Olsson, K. M., Hinrichs, J. B., Thiele, T., Seeliger, T., Skripuletz, T., Schmidt, R. E., Witte, T., Dopfer‐Jablonka, A., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00332 · Cited by 54
Cottin, V., Martinez, F. J., Jenkins, R. G., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Respiratory Research · doi:10.1186/s12931-022-01974-2 · Cited by 53
Lescoat, A., Varga, J., Matucci‐Cerinic, M., & Khanna, D. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1923693 · Cited by 53
Systemic Scleroderma—Definition, Clinical Picture and Laboratory Diagnostics
Kowalska-Kępczyńska, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092299 · Cited by 53
Macrophages as determinants and regulators of fibrosis in systemic sclerosis
Al-Adwi, Y., Westra, J., van Goor, H., Burgess, J. K., Denton, C. P., & Mulder, D. J. (2022) · Rheumatology · doi:10.1093/rheumatology/keac410 · Cited by 54
Systemic Sclerosis Association with Malignancy
Lepri, G., Catalano, M., Bellando-Randone, S., Pillozzi, S., Giommoni, E., Giorgione, R., Botteri, C., Matucci‐Cerinic, M., Antonuzzo, L., & Guiducci, S. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08930-4 · Cited by 53
Sarcoidosis-associated pulmonary fibrosis: joining the dots
Bandyopadhyay, D., & Mirsaeidi, M. S. (2023) · European Respiratory Review · doi:10.1183/16000617.0085-2023 · Cited by 55
Huang, Y., Deng, J., Tian, Y., Liang, J., Xie, X. S., Huang, Y., Zhu, J., Zhu, Z., Zhou, Q., He, X., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01085 · Cited by 52
Lung function trajectory of rheumatoid arthritis–associated interstitial lung disease
Chang, S. H., Lee, J. S., Ha, Y., Kim, M. U., Park, C. H., Lee, J. S., Kim, J., Chung, S. W., Pyo, J. Y., Lee, S. W., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead027 · Cited by 52
Review of indications for immunoglobulin (IG) use: Narrowing the gap between supply and demand
Brand, A., Angelis, V. D., Vuk, T., Garraud, O., Lozano, M., & Politis, D. (2020) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2020.12.005 · Cited by 53
Yoo, H., Hino, T., Han, J., Franks, T. J., Im, Y., Hatabu, H., Chung, M. P., & Lee, K. S. (2020) · European Journal of Radiology Open · doi:10.1016/j.ejro.2020.100311 · Cited by 52
RetractedHyldgaard, C., Bendstrup, E. M., Pedersen, A. B., Pedersen, L. H., & Ellingsen, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10214830 · Cited by 53
Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches
Obi, O. N., Saketkoo, L. A., Russell, A., & Baughman, R. P. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.991783 · Cited by 60
Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease
Perelas, A., Arrossi, A. V., & Highland, K. B. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.05.001 · Cited by 51
Self-citationInterstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention
Fischer, A., Patel, N. M., & Volkmann, E. R. (2019) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s226695 · Cited by 53
Self-citationRecent advances in rheumatoid arthritis-associated interstitial lung disease
Juge, P., Crestani, B., & Dieudé, P. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000710 · Cited by 52
Islam, M. S., Afrin, S., Singh, B., Jayes, F. L., Brennan, J. T., Borahay, M. A., Leppert, P. C., & Segars, J. H. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.475 · Cited by 54
Allanore, Y., Vonk, M. C., Distler, O., Azuma, A., Mayes, M. D., Gahlemann, M., James, A., KOHLBRENNER, V. M., Alves, M., Khanna, D., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222564 · Cited by 50
Self-citationClinical characteristics and outcomes of 566 Thais with systemic sclerosis: A cohort study
Foocharoen, C., Peansukwech, U., Mahakkanukrauh, A., Suwannaroj, S., Pongkulkiat, P., Khamphiw, P., & Nanagara, R. (2020) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13859 · Cited by 50
Chung, L. S., Spino, C., McLain, R. W., Johnson, S. R., Denton, C. P., Molitor, J. A., Steen, V. D., Lafyatis, R., Simms, R. W., Kafaja, S., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30237-x · Cited by 50
Self-citationPDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis
Paolini, C., Agarbati, S., Benfaremo, D., Mozzicafreddo, M., Svegliati, S., & Moroncini, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073904 · Cited by 51
Jee, A. S., & Corte, T. J. (2019) · Drugs · doi:10.1007/s40265-019-01178-x · Cited by 49
Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease
Selva-O’Callaghan, A., Romero-Bueno, F., Araguás, E. T., Gil‐Vila, A., Ruiz‐Rodríguez, J. C., Sánchez‐Pernaute, O., & Pinal‐Fernandez, I. (2021) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-021-00186-x · Cited by 50
Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials
Roofeh, D., Distler, O., Allanore, Y., Denton, C. P., & Khanna, D. (2020) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198320903208 · Cited by 48
Self-citationJAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis
Hou, Z., Su, X., Han, G., Xue, R., Chen, Y., Chen, Y., Wang, H., Yang, B., Liang, Y., & Ji, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.859330 · Cited by 48
Back to the future: targeting the extracellular matrix to treat systemic sclerosis
Leask, A., Naik, A., & Stratton, R. J. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01032-1 · Cited by 50
Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases
Isshiki, T., Naiel, S., Vierhout, M., Otsubo, K., Ali, P., Tsubouchi, K., Yazdanshenas, P., Kumaran, V. R., Dvorkin‐Gheva, A., Kolb, M. R. J., et al. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108578 · Cited by 49
Yu, W.-K., Chen, W., Su, V. Y., Shen, H., Wu, H.-H., Chen, H., & Yang, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158193 · Cited by 48
Walsh, S. L. F., Backer, J. D., Prosch, H., Langs, G., Calandriello, L., Cottin, V., Brown, K. K., Inoue, Y., Tzilas, V., & Estes, E. A. (2024) · European Respiratory Review · doi:10.1183/16000617.0055-2023 · Cited by 47
Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma
Yaseen, B., Lopez, H., Taki, Z., Zafar, S., Rosario, H., Abdi, B. A., Vigneswaran, S., Xing, F., Arumalla, N., Black, S., et al. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa195 · Cited by 47
Diagnosing interstitial lung disease by multidisciplinary discussion: A review
Glenn, L. M., Troy, L. K., & Corte, T. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1017501 · Cited by 47
Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies
Derhovanessian, A., Wallace, W. D., Lynch, J. P., Belperio, J. A., & WEIGT, S. S. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1618567 · Cited by 48
Systemic sclerosis: Recent insight in clinical management
Zanatta, E., Codullo, V., Avouac, J., & Allanore, Y. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2019.09.015 · Cited by 46
Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update
Utsunomiya, A., Oyama, N., & Hasegawa, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113388 · Cited by 47
Maher, T. M., Mayes, M. D., Kreuter, M., Volkmann, E. R., Aringer, M., Castellvi, I., Cutolo, M., Stock, C., Schoof, N., Alves, M., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41576 · Cited by 46
Self-citationNintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Distler, O., Gahlemann, M., & Maher, T. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1910735 · Cited by 46
Self-citationTsitoura, E., Trachalaki, A., Vasarmidi, E., Mastrodemou, S., Margaritopoulos, G. A., Kokosi, M. A., Fanidis, D., Galaris, A., Aidinis, V., Renzoni, E. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645548 · Cited by 44
Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis
Almaaitah, S., Highland, K. B., & Tonelli, A. R. (2020) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s232038 · Cited by 44
Self-citationMachine learning predicts stem cell transplant response in severe scleroderma
Franks, J. M., Martyanov, V., Wang, Y., Wood, T. A., Pinckney, A., Crofford, L. J., Keyes-Elstein, L., Furst, D. E., Goldmuntz, E. A., Mayes, M. D., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217033 · Cited by 44
Self-citationThe Diagnosis and Treatment of Pulmonary Fibrosis
Kreuter, M., Müller-Ladner, U., Costabel, U., Jonigk, D. D., & Heußel, C. P. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0018 · Cited by 46
Ledoult, E., Morelle, M., Soussan, M., MEKINIAN, A., Béhal, H., Sobanski, V., HACHULLA, E., Huglo, D. G., Gouellec, N. L., Rémy-Jardin, M., et al. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02460-8 · Cited by 44
Hoffmann, T., Oelzner, P., Franz, M., Teichgräber, U. K.-M., Renz, D. M., Förster, M., Böttcher, J., Kroegel, C., Schulze, P. C., Wolf, G., et al. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02786-x · Cited by 43
Moinzadeh, P., Bonella, F., Oberste, M., Weliwitage, J., Blank, N., Riemekasten, G., Müller‐Ladner, U., Henes, J. C., Siegert, E., Günther, C., et al. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.08.013 · Cited by 43
Matei, A., Chen, C., Kiesewetter, L., Györfi, A., Li, Y., Trinh‐Minh, T., Xu, X., Manh, C. T., Kuppevelt, T. H. V., Hansmann, J., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216108 · Cited by 47
Doliner, B., Rodriguez, K., Montesi, S. B., Fu, X., Sharma, A., & Wallace, Z. S. (2022) · Rheumatology · doi:10.1093/rheumatology/keac339 · Cited by 43
Knobler, R., Geroldinger‐Simić, M., Kreuter, A., Hunzelmann, N., Moinzadeh, P., Rongioletti, F., Denton, C. P., Mouthon, L., Cutolo, M., Smith, V. M., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19912 · Cited by 42
Surber, M. W., Beck, S., Pham, S., Marsden, A. T., Gandi, S. K., Baily, J. E., & McElroy, M. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101938 · Cited by 44
Metadata
- Authors
- Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., Clerisme-Beaty, E., Stowasser, S., Tetzlaff, K., Kuwana, M., & Maher, T. M.
- Affiliations
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-27
- Volume
- 380
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945521814
- Cited by
- 1,647
- References
- 36
- Citations by year
- 2026: 139 · 2025: 203 · 2024: 215 · 2023: 231 · 2022: 243 · 2021: 299 · 2020: 247 · 2019: 68
- FWCI
- 157.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, tyrosine kinase inhibitors, antifibrotic therapy, forced vital capacity decline, pulmonary fibrosis, diffuse cutaneous systemic sclerosis, skin involvement, quality of life, diarrhea, adverse events, mycophenolate, modified Rodnan skin score, St George's Respiratory Questionnaire
- MeSH terms
- Administration, Oral, Adult, Diarrhea, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Scleroderma, Systemic, Vital Capacity, Lung Diseases, Interstitial, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
